Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Gujarat Kidney And Super Speciality Limited

NSE: GKSLHospital

Share price

₹184.09

+1.87% close of 9 Oct 2026

Market cap ₹1,473 CrP/E 93.0

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

49

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹1,473 Cr

P/E ratio

93.0

P/B ratio

5.8

ROCE

14.5%

ROE

11.5%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹194.2752-week low ₹99.36

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

We do not have three full years of its sales yet, so there is nothing to compare with its sector.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.1 times its growth rate, on earnings growth of 1058%.

Profit growthPrice per ₹1 profitPer 1% growth
Gujarat Kidney And Super Speciality Limited — this one1058%/yr93.0×—
Apollo Hospitals32%/yr55.0×₹1.7
MANIPALHOS22%/yr104.2×₹4.7
Max Healthcare Institute10%/yr57.4×₹5.7
Aster DM Healthcare Limited-1%/yr169.0×—
Fortis Healthcare Limited27%/yr55.7×₹2.1

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Hospital), it ranks 15 of 24 on returns, 1 of 25 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 14.5% on capital, ahead of 38% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the 4 years of cash statements on file it made ₹11 crore of cash from the business but spent ₹29 crore on plant and equipment, ₹18 crore more than it made; the gap was from lenders and shareholders.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 8 checks clear · 88%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 14 Aug 2026 · Consolidated · Unaudited

Revenue

₹34 Cr

Revenue vs last year

+124.7%

Revenue vs last quarter

+12.1%

Net profit

₹5 Cr

Profit vs last year

-1.5%

Profit vs last quarter

+10.4%

Net margin

15.5%

EPS

₹0.66

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹1,473 Cr
Prev close
₹184.09
52w High
₹210
52w Low
₹98.4
Enterprise value
₹1,446 Cr
Beta
0.5
Price CAGR 1y
—
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
5.7%
PEG ratio
0.1
P/E ratio
93.0
P/B ratio
5.8
EV / EBITDA
54.2
Industry P/E
54.3
ROCE
14.5%
ROCE 5y average
28.3%
ROE
11.5%
Debt / Equity
0.1
Interest coverage
11.5
Dividend yield
0.0%
ROE 3y average
16.0%
ROE last year
11.0%

Annual P&L

Annual revenue
₹82 Cr
Annual profit
₹17 Cr
Operating margin
33.0%
Net profit margin
20.7%
EBITDA margin
32.9%
Sales growth 3y
—
Sales growth 5y
—
Profit growth 3y
1058.0%
Profit growth 5y
—
EPS
₹2.0
Sales growth TTM
119.0%
Profit growth TTM
37.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹34 Cr
Profit latest quarter
₹5 Cr
YoY quarterly sales growth
124.7%
YoY quarterly profit growth
-1.5%
OPM latest quarter
24.4%

Balance Sheet

Book Value
₹31.6
Face Value
₹2.0
Total debt
₹29 Cr
Total cash
₹56 Cr
Borrowings
₹29 Cr
Reserves / Equity
14.8

Cash Flow

Operating cash flow
-₹4 Cr
Free cash flow
-₹15 Cr
FCF yield
-1.1%
Net cash flow
₹11 Cr

Shareholding

Promoter holding
71.5%
FII holding
6.5%
DII holding
0.3%
Public holding
21.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Apollo Hospitals7,917.0054.11,13,8340.25610.434.27,043.520.617.4
Manipal Health699.15103.991,9650.00243.4-7.93,090.638.112.1
Max Healthcare908.0059.088,3770.22323.04.92,366.216.714.7
Aster DM Quality680.30164.359,3000.4429.3-46.11,310.721.611.6
Fortis Health.779.1055.158,8190.13272.83.42,545.017.513.4
Narayana Hrudaya1,723.2040.935,2150.26207.35.72,683.678.015.5
Global Health1,294.1060.834,7950.04157.3-0.21,304.126.517.4
Gujarat Kidney187.1293.21,4750.005.37.034.3124.714.5
Median406.3249.35,7570.0230.219.9399.422.314.7

Competes with: Apollo Hospitals, Aster DM Healthcare Limited, Fortis Healthcare Limited, Global Health Limited, Krishna Institute of Medical Sciences Limited, MANIPALHOS, Max Healthcare Institute, Narayana Hrudayalaya Ltd.

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales9.41129.781513233134
Expenses4.557.197.176.647.81162426
Material Cost1.303.053.374.34
Change in Inventories0000
Purchases of Stock-in-Trade0000
Employee Cost2.233.985.355.29
Other Expenses4.289.311616
Operating Profit4.864.602.618.625.126.906.308.37
OPM %5239275640302124
Other Income0.040.050.050.010.090.060.710.69
Exceptional items (within Other Income)0000
Interest0.160.170.160.180.280.600.820.66
Depreciation0.740.880.900.960.901.331.511.44
Profit before tax43.601.607.494.035.034.686.96
Tax %263017282926-2.9924
Net Profit2.962.531.345.402.883.704.825.32
EPS in Rs18160.230.850.470.370.640.66
Diluted EPS in Rs0.520.520.810.66

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2023Mar 2024Mar 2025Mar 2026TTM
Sales054082101
Expenses03245574
Material Cost9.12
Change in Inventories0
Purchases of Stock-in-Trade0
Employee Cost14
Other Expenses32
Operating Profit-02172727
OPM %41413326
Other Income01012
Exceptional items (within Other Income)0
Interest0011.882
Depreciation003.294.705
Profit before tax-02132121
Tax %0252621
Net Profit-02101717
EPS in Rs-0.50861.661.972.14
Diluted EPS in Rs2.49
Dividend Payout %0000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
—
3 years
—
TTM
119%

Compounded profit growth

10 years
—
5 years
—
3 years
1058%
TTM
37%

Return on equity

10 years
—
5 years
—
3 years
16%
Last year
11%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.200.201116
Reserves01115237
Borrowings06829
Other Liabilities442116
Minority Interest2.22
Total Liabilities42155298
Fixed Assets01431129
CWIP0000
Investments00012
Other Assets4724157
Total Assets42155298

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity0114-3.86
Cash from Investing Activity00-18-214
Cash from Financing Activity0-06228
Net Cash Flow01211
Free Cash Flow02-5-15

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2023Mar 2024Mar 2025Mar 2026
Debtor Days321138172
Inventory Days82
Days Payable339
Cash Conversion Cycle321138172
Working Capital Days100-2491
ROCE %195214

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Sep 2026
Line itemDec 2025Mar 2026Jun 2026Sep 2026
Promoters71717171
FIIs104.894.896.52
DIIs1.670.560.560.25
Public16232322
No. of Shareholders27,78318,30118,30112,986

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +76.1% (₹104.54 → ₹184.09)Brick size ₹10.14 (fixed)Bricks 8
₹125₹150₹175₹184May '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹184.09 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-27.00inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Gujarat Kidney And Super Speciality Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Hospital
Classification
Healthcare › Hospital
ISIN
INE0V0W01025

Plants

  • Ashwini Medical Centre · Anand, Gujarat
  • Gujarat Kidney & Super Speciality Hospital
  • Gujarat Multispeciality Hospital · Godhra, Gujarat
  • Gujarat Surgical Hospital · Vadodara, Gujarat
  • Raj Palmland Hospital
  • Surya Hospital & ICU

News impact

Big market events that reach Gujarat Kidney And Super Speciality Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

  • daily-prices repair: 2 rows from NSE's archive (replace 0, delete 1, insert 1), 2026-01-15..2026-02-01 (docs/flat_day_repair.md)1× · 15 Jan 2026

Bulk & block deals

DateWhoBought / soldSharesPrice
7 Oct 2026NATVARSINH T CHAVDASELL4,86,148₹192.19
7 Oct 2026NATVARSINH T CHAVDABUY4,71,148₹188.97
5 Oct 2026NATVARSINH T CHAVDABUY7,21,367₹189.10
5 Oct 2026NATVARSINH T CHAVDASELL7,21,367₹192.11
5 Oct 2026QE SECURITIES LLPBUY4,43,342₹192.61
5 Oct 2026QE SECURITIES LLPSELL4,27,062₹190.48
1 Oct 2026JUNOMONETA FINSOL PRIVATE LIMITEDBUY15,03,223₹198.86
1 Oct 2026JUNOMONETA FINSOL PRIVATE LIMITEDSELL15,02,241₹199.10
1 Oct 2026MICROCURVES TRADING PRIVATE LIMITEDBUY14,98,972₹199.79
1 Oct 2026MICROCURVES TRADING PRIVATE LIMITEDSELL14,98,972₹200.04

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.